This article is more than 5 years old. Information may no longer be current.

Trials of uveitis drug set to begin in 2007

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JERSEY CITY, N.J. — Lux Biosciences Inc. will begin three clinical trials of its calcineurin inhibitor LX211 next year, the company announced in a press release.

The company plans to initiate three controlled, double-masked studies of LX211 in early 2007 to evaluate the drug as a treatment for uveitis in more than 500 patients. Specifically, the studies will evaluate LX211 as a steroid-sparing agent for treating active posterior, intermediate and panuveitis, as a steroid-sparing agent for treating active anterior chamber inflammation, and for controlling inflammation in patients with quiescent posterior, intermediate and panuveitis, according to the release.

Investigators in North America and Europe will participate in the trials, the company said.